CURE Honors World Ovarian Cancer Day

In honor of World Ovarian Cancer Day, which was created in 2013 to raise awareness about the disease, CURE® rounded up the latest news and updates in this cancer space:

• Despite on-treatment clinical progression, patients treated with Avastin (bevacizumab) and standard chemotherapy had a median progression-free survival of 11.8 months compared with 8.8 months in those treated with standard chemotherapy alone.

• In this episode of the “CURE® Talks Cancer” podcast, we spoke with an ovarian cancer survivor and teacher about how she maintained her sense of humor through treatment and why it’s important to remain connected to friends and family, especially during the darkest moments.

• Following chemotherapy with secondary cytoreduction for patients with platinum-sensitive relapsed ovarian cancer contributed to longer progression-free survival compared with chemotherapy alone, according to study results published in The Lancet Oncology.

• Maintenance therapy with a PARP inhibitor demonstrated benefits including progression-free survival for those with high-grade, recurrent, platinum-sensitive ovarian cancer, according to data published in Cancer.

• Fertility treatments led to an ovarian cancer diagnosis but also opened the door to adoption and a new view on life for Elizabeth Johnston, who shared her story with us in our latest Women’s Cancers Special Issue.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.